Intelligencia AI

What Intelligencia AI does

Intelligencia AI is a private SaaS company founded in 2017 and headquartered in New York, with a significant R&D presence in Athens, Greece. The company applies machine learning to assess and mitigate risk in clinical development, producing probability of technical and regulatory success (PTRS) assessments for pharmaceutical and biotechnology organizations. Its core customers are mid-to-large pharmaceutical companies, business development and licensing teams, and R&D program leadership, with secondary exposure to long-range planning, financial markets, and consultancies/CROs. Named enterprise customers include Sanofi and Ionis Pharmaceuticals, and the company cites approximately 110 global employees as of 2024.

The company's product suite is centered on Portfolio Optimizer, an AI-powered SaaS platform that delivers consistent, unbiased PTRS assessments across each stage of drug development, with explainable AI surfacing the drivers behind each prediction. It is complemented by Dynamic Benchmarks (visualization of historical success rates and competitive landscapes back to 1990), Data & Insights (curated, harmonized clinical and biological data with proprietary ontologies covering indication, modality, target, mechanism of action, line of treatment, population, and disease severity), and a Data-as-a-Subscription (DaaS) API for programmatic access. The underlying technology rests on a proprietary database of 1.5 billion+ harmonized data points, daily updates, expert PhD-level curation, and ML models whose methodology is protected by U.S. Patent 11,948,667 (granted April 2024). Validated model performance includes 80%+ prospective and 90% retrospective accuracy for Phase 2 oncology PTRS predictions.

The business operates an enterprise SaaS model with quote-based pricing, dedicated customer success management, and direct field sales in the US and Europe. Revenue streams include annual/multi-year Portfolio Optimizer subscriptions, DaaS subscriptions, and bespoke analytics/consulting engagements. The company has raised approximately $15.5 million across a 2018 round and an August 2021 Series A led by MTIP, with participation from Big Pi Ventures, Synetro Group, and ZS. It has been recognized on the Inc. 5000 (#1819, 2024) for 287% three-year revenue growth, as a Top 100 Healthcare Technology Company (2024), and as a 2025 AI Excellence Award winner.

Name

Intelligencia AI

Legal name

Intelligencia, Inc.

Website

https://intelligencia.ai

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Intelligencia AI is a New York-based SaaS company applying machine learning to assess clinical development risk for pharmaceutical and biotechnology organizations. Its Portfolio Optimizer platform delivers probability of technical and regulatory success assessments, backed by 1.5 billion+ harmonized data points and proprietary ontologies, with named customers including Sanofi and Ionis.

Ownership category

akta.pro rank

Product category

Pharmaceutical R&D Analytics

NAICS

Other Scientific and Technical Consulting Services (54169), Scientific Research and Development Services (5417)

SIC

Services-Prepackaged Software (7372)

akta.pro primary industry

AI Observability, Monitoring & Evaluation Platforms (Drift, Quality, Safety) (HDAEANAF)

akta.pro secondary industry

Audit, Explainability & Accountability Tooling (traceability, reporting) (HDAAAKAL)

Keywords

• AI drug development
• Clinical development analytics
• Pharmaceutical portfolio optimization
• Drug success prediction
• Biomedical data platform

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations

Revenue model

1. SaaS Subscriptions (Portfolio Optimizer): Annual or multi-year subscriptions to the Portfolio Optimizer SaaS platform providing PTRS assessments and portfolio optimization tools.
2. Data-as-a-Subscription (DaaS): Subscription access to curated and harmonized clinical development and biological data via API for customers' own modeling and analytics needs.
3. Bespoke Insight Reports: Custom analytics and consulting engagements delivering scenario analysis and predictive analytics tailored to specific client questions and strategic decisions.

Pricing tiers

Go-to-market motion3 records

Distribution channels3 records

Marketing channels7 records

Core offering

Intelligencia AI is a SaaS company that applies machine learning and proprietary data to assess and mitigate risk in clinical development strategy and design. It provides AI-driven probability of technical and regulatory success (PTRS) assessments, portfolio optimization, competitive benchmarking, and curated clinical and biological data to pharmaceutical and biotechnology organizations.

Product overview

Intelligencia AI offers a suite of AI-powered SaaS solutions for pharmaceutical and biotech companies, centered on its core Portfolio Optimizer platform. The platform is complemented by Dynamic Benchmarks for competitive landscape analysis and Data & Insights services providing curated, harmonized clinical and biological data. The company also offers Data-as-a-Subscription (DaaS) for programmatic access to its proprietary data repository.

Differentiator

Problem solved

Functional benefit

Brands

• Portfolio Optimizer™: AI-powered SaaS solution for pharmaceutical portfolio optimization that enables portfolio leaders, BD&L professionals and competitive intelligence functions to obtain consistent, accurate, and unbiased assessments of the likelihood of drug success at every stage of drug development.

Products and services

• Portfolio Optimizer AI-powered SaaS platform that enables portfolio leaders, BD&L professionals, and competitive intelligence functions to obtain consistent, accurate, and unbiased assessments of the likelihood of a drug's success at every stage of clinical development, with explainable AI showing PTRS drivers.
• Dynamic Benchmarks Data visualization solution providing competitive landscape benchmarking analysis. Enables access to granular, disease-specific historical success rates and phase-by-phase analyses for data-driven clinical development decision-making.
• Data & Insights Expertly curated and harmonized clinical development and biological data solutions, including comprehensive data dictionaries using proprietary ontologies for systematic searching of clinical trial characteristics such as indication, modality, target, mechanism of action, line of treatment, population characteristics, and disease severity.
• Data-as-a-Subscription (DaaS) Subscription-based programmatic access to curated clinical development and biological data via API, with ongoing updates for driving insights and analytics integration into customers' own modeling workflows.
• Bespoke Insight Reports Custom analytics and consulting engagements delivering scenario analysis and predictive analytics tailored to specific client questions and strategic decisions, leveraging Intelligencia AI's proprietary data and models.

Quantifiable outcome

• 83% prospective accuracy for Phase 2 oncology predictions (validated against 2023 announcements)
• +5 more outcomes

Named customers6 records

Segments6 records

Ideal customer profiles5 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

Partnerships

Four partnerships are on record, tiered strategic and minor.

• NovartisstrategicStrategic or Co-development Partner · 1 June 2025Featured in sponsored interview analysis discussing AI applications in pharmaceutical R&D. Executives from both companies participated in discussing AI-driven decision-making and efficiency improvements in drug development.
• ZSstrategicStrategic or Co-development Partner · 1 August 2021Strategic partnership formed in 2021 following Series A funding. ZS is a global professional services firm specializing in consulting and technology solutions for healthcare and life sciences.
• Constructor LearningminorOthersGerry Liaropoulos, Chief AI Officer at Intelligencia AI, serves as a machine learning instructor at Constructor Learning in Zurich.
• Big Blue Data AcademyminorOthersGerry Liaropoulos, Chief AI Officer at Intelligencia AI, serves as an advisor and instructor at Big Blue Data Academy in Athens.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Broad incumbents

• Veeva Systems: Veeva provides cloud software for life sciences, including clinical, regulatory, and quality solutions used by pharma R&D organizations. While not a direct PTRS competitor, it competes for the same enterprise R&D software budget and increasingly expands into clinical development analytics.
• GlobalData: GlobalData provides pharma market intelligence, clinical trial tracking, and competitive intelligence across the drug development value chain, including disease-specific forecasts and pipeline analytics that overlap with Intelligencia AI's PTRS benchmarking offerings.
• IQVIA: IQVIA is the largest contract research and healthcare analytics organization, offering clinical trial operations, real-world data, and AI-driven R&D analytics at massive scale. It competes with Intelligencia AI in pharma R&D intelligence, though at a vastly broader portfolio and price point.
• Informa Pharma Intelligence: Informa Pharma Intelligence (PharmaProjects, Citeline legacy, Trialtrove, Pharmaprojects) offers trial, pipeline, and drug development intelligence to pharma enterprises. It competes with Intelligencia AI's Dynamic Benchmarks and Portfolio Optimizer as part of a broader intelligence suite.
• Clarivate: Clarivate offers pharma intelligence, clinical trial analytics, IP analytics, and regulatory workflow tools covering drug development lifecycle from discovery through commercialization. It is a much broader incumbent than Intelligencia AI but competes for the same R&D strategy budget.
• Norstella (parent of Evaluate and Citeline): Norstella aggregates pharma commercial intelligence, clinical trial data, and forecasting through its Evaluate and Citeline brands, directly overlapping with Intelligencia AI's PTRS and clinical benchmarking offerings but at much greater scale and breadth. Intelligencia AI's CPO Jon Moser was previously Chief Innovation Officer at Norstella/Evaluate, evidencing deep category overlap.

Others

• ZS Associates: ZS is a global consulting and technology firm specializing in pharma/life sciences commercial and R&D strategy, and is both an Intelligencia AI strategic partner (formed in 2021) and a participating investor in the $12M Series A. It is comparable as a pharma R&D advisory channel and overlapping service provider.

Emerging players

• Trial Library: Trial Library is an emerging clinical trial feasibility and site selection platform that intersects with Intelligencia AI's trial design and benchmarking use cases. It is comparable as an emerging SaaS player targeting clinical development decision-making in pharma.

Direct peers

• Citeline (Norstella): Citeline provides clinical trial intelligence, drug development pipeline tracking, and pharma R&D analytics — overlapping with Intelligencia AI's Dynamic Benchmarks and Portfolio Optimizer for enterprise pharma buyers seeking competitive landscape and trial success data.
• Airfinity: Airfinity is a London-based health intelligence company providing disease forecasting, clinical trial analytics, and pharma R&D data — directly competing with Intelligencia AI in clinical development intelligence. Notably, Intelligencia AI's CPO Jon Moser was formerly CPO at Airfinity, making it a near-direct peer in product and target market.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/intelligencia-ai

Revenue estimate

Valuation estimate

Number of profiles

Profiles12 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Intelligencia AI